Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta;42 in humans

Annals of Neurology

Volumn 59, Issue 3, 2006, Pages 512-519

  Fagan, Anne M ^a   Mintun, Mark A ^a   Mach, Robert H ^a   Lee, Sang Yoon ^a   Dence, Carmen S ^a   Shah, Aarti R ^a   LaRossa, Gina N ^a   Spinner, Michael L ^a   Klunk, William E ^b   Mathis, Chester A ^b   DeKosky, Steven T ^b   Morris, John C ^a   Holtzman, David M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BENZOTHIAZOLE DERIVATIVE; BIOLOGICAL MARKER; PITTSBURGH COMPOUND B; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID EXAMINATION; CLINICAL ARTICLE; CLINICAL EXAMINATION; COGNITIVE DEFECT; DIAGNOSTIC KIT; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMAGING; IMAGING SYSTEM; IN VIVO STUDY; PATHOGENESIS; PATIENT CODING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; SENILE PLAQUE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID; AMYLOID BETA-PROTEIN; DIAGNOSTIC IMAGING; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PEPTIDE FRAGMENTS; TISSUE DISTRIBUTION;

EID: 33644832047     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20730     Document Type: Article

References (29)

1. Gandy S, Petanceska S. Regulation of Alzheimer beta-amyloid precursor trafficking and metabolism. Biochim Biophys Acta 2000;1502:44-52.
2. Morris J, Price J. Pathologic correlates of noudemented aging, mild cognitive impairment, and early stage Alzheimer's disease. J Mol Neurosci 2001;17:101-118.
3. Hulette CM, Welsh-Bohmer KA, Murray MG, et al. Neuropathological and neuropsychological changes in "normal" aging: evidence for preclinical Alzheimer disease in cognitively normal individuals. J Neuropathol Exp Neurol 1998;57:1168-1174.
4. Morris J, McKeel D, Fulling K, et al. Validation of clinical diagnostic criteria for Alzheimer's disease. Ann Neurol 1988;24:17-22.
5. Berg L, McKeel DW, Miller JP, et al. Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apoE genotype. Arch Neurol 1998;55:326-335.
6. Morris JC. The Clinical Dementia Rating (CDR). Current version and scoring rules. Neurology 1993;43:2412-2414.
7. Morris J, Storandt M, Miller J, et al. Mild cognitive impairment represents early-stage Alzheimer's disease. Arch Neurol 2001;58:397-405.
8. Klunk W, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-319.
9. Fagan A, Younkin L, Morris J, et al. Differences in the Aβ40/Aβ42 ratio associated with cerebrospinal fluid lipoproteins as a function of apolipoprotein E genotype. Ann Neurol 2000;48:201-210.
10. Cirrito J, May P, O'Dell M, et al. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-β metabolism and half-life. J Neurosci 2003;23:8844-8853.
11. 11C-labeled 6-substituted 2-arylbenzothiazoles as amyloid imaging agents. J Med Chem 2003;46:2740-2754.
12. Snyder A. Difference image versus ratio image error function forms in PET-PET realignment. In: Myers R, Cunningham V, Bailey D, Jones T, eds. Quantification of brain function using PET. San Diego: Academic Press, 1996:131-137.
13. Logan J, Fowler J, Volkow N, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 1996;16:834-840.
14. Price J, Klunk W, Lopresti B, et al. Kinetic modeling of amyloid binding in humans using PET imaging and Pittsburgh Compound-B. J Cereb Blood Flow Metab. 2005;25:1528-1547.
15. Price J, Klunk W, Lopresti B, et al. PIB PET amyloid imaging in Alzheimer's disease and mild cognitive impairment. J Nucl Med 2005;46(suppl 2):123P.
16. McKhann G, Albert M, Grossman M, et al. Clinical and pathological diagnosis of frontotemporal dementia: Report of the Work Group on Frontotemporal Dementia and Pick's Disease. Arch Neurol 2001;58:1803-1809.
17. Kawarabayashi T, Younkin L, Saido T, et al. Age-dependent changes in brain, CSF, and plasma amyloid protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 2001;21:372-381.
18. DeMattos RB, Bales KR, Parsadanian M, et al. Plaque-associated disruption of CSF and plasma amyloid-β (Aβ) equilibrium in a mouse model of Alzheimer's disease. J Neurochem 2002;81:229-236.
19. Gomez-Isla T, Price JL, McKeel DW, et al. Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer's disease. J Neurosci 1996;16:4491-4500.
20. Price J, Ko A, Wade M, et al. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer's disease. Arch Neurol 2001;58:1395-1402.
21. Ganguli M, Rodriguez E, Mulsant B, et al. Detection and management of cognitive impairment in primary care: the Steel Valley Seniors Survey. J Am Geriatr Soc 2004;52:1668-1675.
22. 1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer's disease. JAMA 2003;289:2094-2103.
23. DeMattos RB, Bales KR, Cummins DJ, et al. Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 2002;295:2264-2267.
24. Mayeux R, Tang M, Jacobs D, et al. Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol 1999;46:412-416.
25. Mayeux R, Honig L, Tang M, et al. Plasma Aβ40 and Aβ42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 2003;61:1185-1190.
26. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease. Ann Neurol 1999;45:358-368.
27. Storandt M, Grant E, Miller J, Morris J. Rates of progression in mild cognitive impairment and early Alzheimer's disease. Neurology 2002;59:1034-1041.
28. Ringman J, Diaz-Olavarrieta C, Rodriguez Y, et al. Neuropsychological function in nondemented carriers of presenilin-1 mutations. Neurology 2005;65:552-558.
29. Golde T. Alzheimer disease therapy: can the amyloid cascade be halted? J Clin Invest 2003;111:11-18.